ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1279

Anti-IL-6 Receptor Antibody Is Effective In Arthritis Regardless Of Obesity In Mouse Model

Miho Suzuki, Hiroto Yoshida and Yoshihiro Matsumoto, Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: arthritis management, IL-6, Macrophage, obesity and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Compared with non-obese patients, obese patients with rheumatoid arthritis (RA) reportedly experience worsening of symptoms [Arthritis Care Res (Hoboken). 2013; 65: 78-87] and do not respond as well to TNF inhibitors [Arthritis Rheum. 2011; 63: 359-64, Arthritis Care Res (Hoboken). 2013; 65: 94-100]. However, the efficacy of IL-6 inhibition in the treatment of RA under conditions of obesity has not yet been fully examined. In this study, we investigated the response to IL-6 inhibition in an obese mouse model of collagen-induced arthritis (CIA).

Methods:

1) To prepare a model of obesity, mice were fed a high-fat diet for 5 weeks. The level of mRNA expression of macrophage marker F4/80 in hind limbs of non-collagen-immunized obese and non-obese mice was measured by real-time PCR. CIA was then induced according to a previously described method [Arthritis Rheum. 1998; 41: 2117-21]. We treated CIA mice with anti-IL-6 receptor antibody (anti-IL-6R) and TNF inhibitor TNFR-Fc. Clinical symptoms of arthritis were evaluated by observation and expressed as an arthritis score on a scale of 0–4 for each limb. The level of cyclooxygenase (COX)-2 mRNA expression as a parameter of inflammation was measured by real-time PCR in hind limbs of mice at the peak of arthritis. 2) The mouse macrophage cell line RAW264.7 and synovial cells from non-obese CIA mice were cultured with IL-6 or TNF-α for 24 h. After culture, to evaluate the inflammatory response, expression level of COX-2 mRNA was determined by real-time PCR.

Results:

1) We confirmed that obesity was induced by the 5-week high-fat diet (relative body weight: 125%). At this time the expression of F4/80 mRNA was higher in obese mice than in non-obese mice. Moreover, arthritis scores were relatively higher (but not significantly) in obese mice than in non-obese mice at the peak of arthritis (Day 33). Anti-IL-6R significantly inhibited the arthritis scores on Day 33 in both obese (87% inhibition) and non-obese mice (62% inhibition). On the other hand, TNFR-Fc significantly inhibited the arthritis scores on Day 33 in non-obese mice (64% inhibition) but not obese mice (54% inhibition). The expression level of COX-2 mRNA correlated well with arthritis score and was higher in obese mice than in non-obese mice on day 33. 2) Expression of COX-2 mRNA was dramatically increased by IL-6 in RAW cells and by TNF-α in synovial cells.

Conclusion: We demonstrated that there is the potential for inflammation to be increased by obesity and that the anti-arthritis effect of TNFR-Fc was reduced in obese mice, as has been shown in clinical reports. We also demonstrated that anti-IL-6R was effective in this mouse model regardless of whether the mice were obese. One reason might be that obesity promotes macrophage infiltration, and IL-6 is prominently involved in the inflammatory response of macrophages in mice. It goes without saying that it is essential for every patient to reduce excess weight not only because of its risk of exacerbating inflammation but also because of its association with risk of developing other diseases such as cardiovascular disease and diabetes. However, anti-IL-6R has the potential to be useful in the treatment of all RA patients, even those who are obese.


Disclosure:

M. Suzuki,
None;

H. Yoshida,
None;

Y. Matsumoto,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-il-6-receptor-antibody-is-effective-in-arthritis-regardless-of-obesity-in-mouse-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology